Don't Sleep On Pfizer: The Turnaround Is Just Getting Started

Pfizer's Q1 earnings significantly surpassed estimates, despite a revenue miss, primarily due to aggressive structural cost-cutting. The company is expanding its cost-savings program to a substantial $7.7 billion by 2027, aiming to drive EPS growth even with anticipated flat revenues. This strategic focus on operational excellence, combined with robust double-digit growth in its non-COVID portfolio, suggests underlying business strength and a potential valuation upside of nearly 29% from current levels, which the market may be underappreciating.

Analysis

Pfizer's first-quarter performance presented a clear strategic pivot, characterized by a significant earnings beat despite a revenue miss. This bottom-line outperformance was driven by an aggressive structural cost-cutting program, which management is now expanding with a target of $7.7 billion in savings by 2027. The strategy indicates a shift towards prioritizing operational efficiency and margin expansion to fuel EPS growth, even amid projections of flat revenue. The underlying health of the core business appears robust, demonstrated by strong double-digit growth in its non-COVID portfolio, including key drugs Nurtec and Padcev. The article posits that the market has already priced in future patent cliffs and may be overlooking this fundamental strength. A Dividend Discount Model referenced in the source suggests a potential fair value of over $31 per share, implying a valuation upside of nearly 29% from current levels.

Key Decisions for Investors

• Investors should evaluate Pfizer based on its ability to execute its $7.7 billion cost-savings program and drive margin expansion, as this is positioned as the primary catalyst for future EPS growth.
• Consider the potential for valuation upside, as the article's analysis suggests the market may be undervaluing the core non-COVID business by focusing excessively on revenue trends and future patent cliffs.
• Closely monitor the quarterly performance of the non-COVID drug portfolio, particularly growth drivers like Nurtec and Padcev, as their sustained momentum is a critical proof point for the underlying business health thesis.